OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Ghia on the Key Takeaways of the CAPTIVATE Study in Treatment-Naïve CLL

January 3rd 2022

Paolo Ghia, MD, PhD, discusses the key takeaways of the phase 2 CAPTIVATE study in chronic lymphocytic leukemia.

Dr. Ratan on the Steps of Diagnosing Desmoid Tumors

January 3rd 2022

Ravin Ratan, MD, MEd, discusses the steps that should be taken to diagnose desmoid tumors.

Dr. Galsky the Evolution of Standard Options in Urothelial Carcinoma

December 23rd 2021

Matthew Galsky, MD, discusses the evolution of standard of care treatment options in urothelial carcinoma.

Dr. Sherbenou on Future Directions With Maintenance Therapy in Multiple Myeloma

December 23rd 2021

Daniel Sherbenou, MD, PhD, discusses future directions with maintenance therapy in patients with relapsed/refractory multiple myeloma who received CAR T-cell therapy.

Dr. Spaggiari on the Potential Utility of Liver Transplantation in CRC With Liver Metastases

December 23rd 2021

Mario Spaggiari, MD, discusses the potential utility of liver transplantation as a treatment option for patients with colorectal cancer liver metastases.

Dr. Johnson on New Drug Approvals for EGFR Exon 20 Insertion Mutation+ NSCLC

December 23rd 2021

Melissa L. Johnson, MD, discusses new drug approvals for EGFR exon 20 insertion mutation–positive non–small cell lung cancer.

Dr. Banerjee on the Rationale to Create a Supportive Mobile Health App for CAR T-Cell Therapy

December 23rd 2021

Rahul Banerjee, MD, discusses the rationale to create a supportive mobile health companion app for CAR T-cell therapy recipients and their caregivers to use throughout the therapeutic process.

Dr. Gold on Current Unmet Needs in Squamous Cell Carcinoma of the Lung

December 23rd 2021

Kathryn A. Gold, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses current unmet needs in squamous cell carcinoma of the lung.

Dr. Bekaii-Saab on the Benefits Derived With Bevacizumab Plus TAS-102 in mCRC

December 22nd 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses the addition of bevacizumab to trifluridine/tipiracil in patients with metastatic colorectal cancer

Dr. Gold on Leveraging Sotorasib in KRAS G12C–Mutated NSCLC

December 22nd 2021

Kathryn Gold, MD, discusses best practices with the use of sotorasib in patients with KRAS G12C–mutated non–small cell lung cancer.

Dr. Riedell on an Analysis Evaluating the Effect of Time to Relapse on OS in MCL

December 22nd 2021

Peter Riedell, MD, discusses the patient population and design of a dynamic landmark analysis conducted in patients with mantle cell lymphoma.

Dr. Rimawi on the Clinical Implications of the FeDeriCa Trial in Early-Stage HER2+ Breast Cancer

December 22nd 2021

Mothaffar Fahed Rimawi, MD, discusses the clinical implications of the phase 3 FeDeriCa trial in early-stage, HER2-positive breast cancer.

Dr. Shadman on the Safety Profile of a CD20-Directed CAR T-Cell Therapy in B-NHL and CLL

December 22nd 2021

Mazyar Shadman, MD, MPH, discusses the safety profile of MB-106, a third-generation, CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Dr. Zurita-Saavedra on Emerging Frontline Therapies in Metastatic HSPC

December 22nd 2021

Amado J. Zurita-Saavedra, MD, discusses emerging frontline therapies in metastatic hormone-sensitive prostate cancer.

Dr. Fernandez on the Utility of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

December 22nd 2021

Aileen I. Fernandez, PhD, discusses the utility of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Dr. Danila on Examining Immunotherapy in Early-Stage Prostate Cancer

December 22nd 2021

Daniel C. Danila, MD, discusses the rationale for examining immunotherapy in early-stage prostate cancer.

Dr. Ghia on the Design of the CAPTIVATE Study in Treatment-Naïve CLL

December 22nd 2021

Paolo Ghia, MD, PhD, discusses the design of the phase 2 CAPTIVATE study in treatment-naïve chronic lymphocytic leukemia.

Dr. Hurvitz on the Key Objectives of DESTINY-Breast03 in HER2+ Breast Cancer

December 21st 2021

Sara A. Hurvitz, MD, discusses the rationale for the phase 3 DESTINY-Breast03 trial examining in HER2-positive breast cancer.

Dr. Heyman on Ibrutinib Plus Venetoclax in Relapsed/Refractory MCL

December 21st 2021

Benjamin Heyman, MD, discusses the phase 3 SYMPATICO trial examining the combination of ibrutinib and venetoclax vs ibrutinib alone in patients with relapsed or refractory mantle cell lymphoma.

Dr. Dorff on the Clinical Implications of the ARAMIS Trial in Nonmetastatic CRPC

December 21st 2021

Tanya Dorff, MD, discusses the clinical implications of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.